Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 18.9 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.012355% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.009867% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6793.4 |
| Open | 6778.7 |
| 1-Year Change | 19.41% |
| Day's Range | 6628.5 - 6869 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 6789.8 | -21.4 | -0.31% | 6811.2 | 6878.3 | 6748.4 |
| Mar 31, 2025 | 6793.4 | -15.8 | -0.23% | 6809.2 | 6856.6 | 6735.7 |
| Mar 28, 2025 | 6998.7 | 6.4 | 0.09% | 6992.3 | 7016.3 | 6932.4 |
| Mar 27, 2025 | 7024.0 | -4.1 | -0.06% | 7028.1 | 7125.9 | 6993.2 |
| Mar 26, 2025 | 7065.0 | 51.8 | 0.74% | 7013.2 | 7170.9 | 7013.1 |
| Mar 25, 2025 | 7028.0 | -7.0 | -0.10% | 7035.0 | 7075.1 | 6958.1 |
| Mar 24, 2025 | 6897.2 | -78.0 | -1.12% | 6975.2 | 7004.2 | 6882.3 |
| Mar 21, 2025 | 6883.2 | 136.7 | 2.03% | 6746.5 | 6955.5 | 6746.3 |
| Mar 19, 2025 | 6729.4 | -72.9 | -1.07% | 6802.3 | 6846.8 | 6723.4 |
| Mar 18, 2025 | 6822.2 | -98.0 | -1.42% | 6920.2 | 6952.1 | 6796.3 |
| Mar 17, 2025 | 6855.2 | -117.9 | -1.69% | 6973.1 | 6976.1 | 6850.2 |
| Mar 14, 2025 | 6894.1 | 92.9 | 1.37% | 6801.2 | 6946.2 | 6748.2 |
| Mar 13, 2025 | 6897.1 | -29.0 | -0.42% | 6926.1 | 7037.0 | 6893.1 |
| Mar 12, 2025 | 6949.1 | 116.9 | 1.71% | 6832.2 | 7026.1 | 6822.3 |
| Mar 11, 2025 | 6788.3 | 286.8 | 4.41% | 6501.5 | 6790.9 | 6458.6 |
| Mar 10, 2025 | 6728.3 | -196.8 | -2.84% | 6925.1 | 6952.1 | 6658.3 |
| Mar 7, 2025 | 6990.4 | -71.6 | -1.01% | 7062.0 | 7073.0 | 6902.1 |
| Mar 6, 2025 | 7365.7 | -50.9 | -0.69% | 7416.6 | 7480.9 | 7352.8 |
| Mar 5, 2025 | 7491.6 | 71.0 | 0.96% | 7420.6 | 7543.9 | 7328.7 |
| Mar 4, 2025 | 7422.5 | -164.4 | -2.17% | 7586.9 | 7605.0 | 7374.7 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com